Eli Lilly's Foundayo won backing from a European Medicines Agency panel for obesity and type 2 diabetes, challenging Novo Nordisk (CPSE:NOVO B) in Europe. The panel endorsement covers use of Foundayo for patients with obesity and type 2 diabetes across European Union member states, pending formal approval. Foundayo does not require meal timing restrictions, which contrasts with Novo Nordisk's oral semaglutide regimen that includes food related guidance. The EMA panel support for Eli Lilly's Foundayo and its meal flexibility is a key development to weigh against our wider views on Novo Nordisk. We have also flagged 3 warning signs (2 major) for Novo Nordisk.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.